MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith Purchases 25,000 Shares

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith purchased 25,000 shares of the stock in a transaction on Friday, December 13th. The shares were purchased at an average price of $1.87 per share, with a total value of $46,750.00. Following the acquisition, the director now owns 1,130,060 shares in the company, valued at approximately $2,113,212.20. The trade was a 2.26 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

MAIA Biotechnology Stock Down 0.5 %

MAIA opened at $2.00 on Friday. The firm has a market cap of $50.66 million, a PE ratio of -1.45 and a beta of 0.14. MAIA Biotechnology, Inc. has a twelve month low of $0.85 and a twelve month high of $5.99.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.21. As a group, research analysts anticipate that MAIA Biotechnology, Inc. will post -1.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MAIA Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd bought a new position in shares of MAIA Biotechnology during the 3rd quarter worth about $31,000. Ground Swell Capital LLC acquired a new position in MAIA Biotechnology during the 2nd quarter worth approximately $56,000. Finally, Geode Capital Management LLC boosted its holdings in MAIA Biotechnology by 22.9% in the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock worth $541,000 after acquiring an additional 35,821 shares in the last quarter. 5.65% of the stock is currently owned by institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.